UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 8-K/A
                                (Amendment No. 1)

                                 CURRENT REPORT
     Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported): July 15, 2005

                           Applied DNA Sciences, Inc.
                           --------------------------
             (Exact name of registrant as specified in its charter)



          Nevada                       002-90539               59-2262718
- --------------------------------------------------------------------------------
(State or other jurisdiction     (Commission File Number)      (IRS Employer
     of incorporation)                                       Identification No.)


             9229 Sunset Boulevard, Suite 83, Los Angeles, CA 90069
              (Address of principal executive offices and Zip Code)

        Registrant's telephone number, including area code (310) 860-1362

                                   Copies to:
                              Andrea Cataneo, Esq.
                       Sichenzia Ross Friedman Ference LLP
                           1065 Avenue of the Americas
                            New York, New York 10018
                              Phone: (212) 930-9700
                               Fax: (212) 930-9725

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))



Item 1.01 Entry into a Material Definitive Agreement.
Item 1.02 Termination of a Material Definitive Agreement.
Item 2.01 Completion of Acquisition of Assets.
Item 2.03 Creation of a Direct Financial Obligation.

     The  information  set forth under Item 1.01,  1.02,  2.01 and 2.03 filed by
Applied DNA Sciences, Inc. (the "Company") on July 21, 2005 (the "Form 8-K"), is
incorporated herein by reference.

Item 4.02 Non-Reliance on Previously Issued Financial Statements

     On July 11, 2005,  the Company  determined  there were errors in accounting
for the valuation of equity consulting service  transactions  during the January
through March 2005 time period.  The valuation  resulted in the overstatement of
approximately $2.9 million in services  provided.  The errors were discovered in
connection  with a comment  raised by the  Securities  and  Exchange  Commission
("SEC") in their review and comment on our registration  statement on Form SB-2.
The SEC requested that we provided additional  disclosure regarding issuances of
common stock to  non-employees  in exchange for  services.  Upon  reviewing  and
updating our  disclosure,  we discovered  our errors.  Upon this  determination,
management   and  the  board  of  directors   were  alerted  to  the  facts  and
circumstances  regarding  the errors in  valuation.  Authorized  officers of the
Company discussed this matter with the Company's  independent  public accounting
firm who agreed that the Company's quarterly financials could not be relied upon
and needed to be  restated.  On August 3,  2005,  the  Company  filed an amended
10-QSB for the  quarter  ended March 31,  2005 with the SEC which  included  the
amended financials.

Item 5.02 Departure of Directors or Principal Officers

     The  information  set forth under Item 5.02 of the Form 8-K is incorporated
herein by reference.

Item 9.01 Financial Statements and Exhibits.

(a)      Financial statements of business acquired.

         Not applicable.

(b)      Pro forma financial information.

         Pro forma financial information to be provided by amendment.

(c)      Exhibits.

Exhibit Number        Description
- -------------- -----------------------------------------------------------------

4.1            Warrant,  dated as of June 20,  2005,  issued to Trilogy  Capital
               Partners, Inc. *

10.1           Stock Purchase Amendment Agreement, dated as of July 12, 2005, by
               and between  Applied DNA Sciences,  Inc. and Biowell  Technology,
               Inc. *

10.2           License  Agreement,  dated as of July 12,  2005,  by and  between
               Applied DNA Sciences, Inc. and Biowell Technology, Inc. *

10.3           Consulting  Agreement,  dated as of July 12, 2005, by and between
               Applied DNA Sciences, Inc. and Timpix International Limited *

10.4           Letter of  Engagement,  dated as of June 20, 2005, by and between
               Applied DNA Sciences, Inc. and Trilogy Capital Partners, Inc. *

99.1           Letter of Resignation from Rob Hutchison *

* Previously filed on the Form 8-K

                                       2

SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                      Applied DNA Sciences, Inc.


Date: August 4, 2005                  /s/ PETER BROCKLESBY
                                      --------------------
                                      Peter Brocklesby
                                      President


                                       3